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Concise overview of the clinical pharmacokinetics of dideoxynucleoside 
antiretroviral agents
David M. B u rge r, P ie te r L. M e e n h o rs t and Jos H. Beijnen
Introduction
In this paper a concise review will be given of the 
clinical pharmacokinetics of the dideoxynucleoside 
antiretroviral agents zidovudine (AZT, Retrovir®), 
didanosine (ddl, Videx®) and zalcitabine (ddC, 
Hivid®) (Fig. 1). These agents have now been li­
censed in most European countries for the treatment 
of infection with the human immunodeficiency virus 
(HIV), the causative agent of the acquired immuno­
deficiency syndrome (AIDS). Zidovudine delays pro­
gression of HIV infection and prolongs survival in 
patients with AIDS [1], Switching from zidovudine to 
didanosine [2 3] or to zalcitabine [4] therapy has 
been shown to be clinically beneficial after pro­
longed use of zidovudine, whereas combination ther­
apy with zidovudine and didanosine [5] or with zido­
vudine and zalcitabine [6] results in more prolonged 
increases in CD4+ T-lymphocyte counts than with 
these agents in monotherapy. Therefore, these three 
drugs will remain the mainstay of antiretroviral drug 
treatment for the near future and a thorough knowl­
edge of the clinical pharmacokinetics is needed to 
optimize their therapeutic use. In this short review 
special attention will be paid to possibly altered 
pharmacokinetics in special circumstances, such as 
hepatic and renal dysfunction, pregnancy, stage of 
disease, etc The relevance of therapeutic drug moni­
toring of antiretroviral agents to support the pharma­
cotherapy of patients with HIV infection is discussed 
at the end of this review. Related reviews on this sub­
ject can be found in the literature [7-12], A summary 
of the pharmacokinetic parameters of the three 
drugs is presented in Table 1. A review of possible 
drug-drug interactions involving antiretroviral agents 
will be the subject of a forthcoming paper.
Zidovudine
Absorption
Zidovudine is rapidly and completely absorbed after 
oral administration, but first-pass metabolism re­
duces the oral bioavailability to about 65%. Several 
investigators have demonstrated that concomitant 
ingestion of zidovudine capsules with food influences 
the pharmacokinetic parameters of zidovudine [1 3- 
16]. A high-fat meal [13], breakfast [14 16], or a pro­
tein-rich meal [15] reduces the maximum plasma 
concentration (Cmax) of zidovudine and delays the 
time to achieve Cmax (fmax)- However, the total 
absorption of zidovudine [measured as the area 
under the concentration-time curve (AUC)] was only 
slightly, or not, diminished in these studies, which 
had a sufficient sampling interval to calculate the 
AUC [14-16]. Although patients prefer the ingestion 
of zidovudine capsules with food to avoid gastro­
intestinal side-effects, this cannot be recommended 
as long as the relevance of decreased Cmax levels has 
not been established.
A decreased absorption of zidovudine has been
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Abstract
In this paper aspects of the clinical pharmacokinetics of the 
antiretroviral agents zidovudine, didanosine and zalcitabine 
are reviewed. Special attention is paid to possibly altered 
pharmacokinetics in special circumstances, such as hepatic 
and renal dysfunction, pregnancy, stage of disease, etc, The 
dideoxynucleoside antiretroviral agents have some clinical 
pharmacokinetic properties in common (rapid absorption 
and elimination), but substantial differences exist in their 
degree of absorption, metabolism and penetration into the 
cerebrospinal fluid. All agents display wide interpatient 
variability in pharmacokinetic parameters. The relevance of 
therapeutic drug monitoring of antiretroviral agents is also 
discussed.
Accepted November 1994.
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A Figure 1
Zidovudine (left), didanosine (centre) and zalcitabine (right)
found in patients with mild to severe diarrhoea [17; 
Kapembwa et ai, unpublished observations]. Because 
zidovudine is relatively water soluble, differences in 
gastrointestinal transit time are thought to be the 
underlying mechanism of this decreased absorption 
pattern [17],
Distribution
Plasma protein binding of zidovudine is low, 7-38%. 
Zidovudine is widely distributed throughout body 
water and tissues, with a volume of distribution at 
steady state (Vss) of approximately 1.8 l/kg. It has 
been hypothesized that l/ss is lower in patients with 
AIDS than in asymptomatic HIV-infected individuals. 
The reason for this difference is unclear, but may be 
related to disease-induced changes in body compo­
sition [18]. The resulting higher plasma concen­
trations of zidovudine in patients with more ad­
vanced disease may then lead to greater toxicity.
The distribution of zidovudine into specific com­
partments has been the subject of several investi­
gations. The distribution of zidovudine into semen 
has been associated with a decreased detection of 
HIV in the semen of men with CD4 counts lower
Table 1 Pharmacokinetic parameters [7-12]
Parameter* Zidovudine Didanosine Zalcitabine
F (%) 65 40 -50 80
0™ (mg/l) 0.5-1 0.8- 1.2 0.010-0.015
n^ax (h) 0.5-1 1 1
f1/2 (h) 1 1-2 1-2
CL (I h-^kg-1) 1.5-2.0 1 0.2 -0.3
V» 0/kg) 1.5-2.5 0.8- 1.2 0.5
PB (%) 20 <5 <5
fur (% ) 15 -20 10-40 75
*F: oral bioavailability; Cmax: maximum plasma concentration [plasma 
levels at fmax after standard oral doses of zidovudine (200 mg), 
didanosine (200 mg) or zalcitabine (0.75 mg)]; tmx: time to maxi­
mum concentration; t1/2: terminal elimination half-life; CL: total body 
clearance; ya: steady-state volume of distribution; PB: protein bin­
ding; fur: urinary recovery of parent drug.
than 200 per ¡ai [19]. Zidovudine distribution into 
saliva [20] is of particular interest because the ease of 
collection and avoidance of blood handling could 
make saliva a favourable matrix for therapeutic drug 
monitoring.
Zidovudine crosses the placenta and has been 
measured in neonatal blood [21-23]. It is not yet 
known whether pregnancy affects the pharmaco­
kinetics of zidovudine. In one study, an increase in Vss 
and in zidovudine clearance during pregnancy was 
explained by the usual increase in body weight, 
plasma volume and renal and hepatic blood flow 
seen during pregnancy [21]. The pharmacokinetics 
of zidovudine were also monitored 3-4 weeks post­
partum and at that time the pharmacokinetic par­
ameters were no longer different from those re­
ported in HIV-infected men. In another study, 
pharmacokinetic parameters during pregnancy were 
similar to those reported in HIV-infected men [22]. It 
should be noted that this comparison does not 
account for any influence of sex on the clearance of 
zidovudine. It is still not known whether zidovudine 
penetrates into breast milk.
Finally, an important compartment in zidovudine 
pharmacokinetics is the cerebrospinal fluid (CSF). 
Zidovudine has been measured in CSF in relatively 
high concentrations [24]. This supports a role for 
zidovudine in the treatment and prevention of HIV- 
related neurological disorders.
Metabolism and excretion
Zidovudine is extensively metabolized in the liver to 
the inactive glucuronide of zidovudine, which is 
excreted renally (Fig. 2). Its elimination half-life is 
similar to that of the parent compound (~ 1 h), 
which may indicate formation-limited elimination of 
zidovudine glucuronide. Zidovudine glucuronide 
concentrations in plasma are usually higher than 
those of zidovudine, probably due to a smaller for 
zidovudine glucuronide. Approximately 15-20% of 
an oral zidovudine dose is excreted unchanged in 
the urine and approximately 75% as zidovudine glu­
curonide. Extrahepatic metabolism of zidovudine to 
zidovudine glucuronide has been demonstrated in 
human renal and gut microsomes [25].
It has been assumed for a long time that zido­
vudine glucuronide is the only metabolite of zido-
vüdine; however, it has recently been demonstrated 
that two other metabolites of zidovudine can be 
found in plasma, namely, 3,-amino-3'-deoxythymi- 
dine and its glucuronide, which are formed by the 
reduction of the azido moiety in zidovudine and 
zidovudine glucuronide [26].
On the basis of the pharmacokinetic profile of 
zidovudine, it can be expected that zidovudine elim­
ination is decreased in hepatic dysfunction, but not, 
or only marginally, in renal dysfunction. This state­
ment requires some refinement A reduced clearance 
of zidovudine has indeed been found in patients with 
various types of liver disease [27 28]; however, there 
are also data that the elimination half-life ( t^ )  of 
zidovudine is prolonged and that the clearance is 
reduced in patients with severe renal impairment 
[29-31]. The reduction in clearance appears larger 
than the expected 15-20% contribution of the kid­
neys to the total body clearance. Zidovudine glucu­
ronide levels are very high in patients with severe 
renal dysfunction. Haemodialysis removes zidovudine 
glucuronide from plasma, but it has only a marginal 
effect on zidovudine levels, Because of the reduced 
clearance of zidovudine and the negligible effect of 
haemodialysis on zidovudine levels, patients with 
end-stage renal disease and haemodialysis should 
receive lower doses than patients with normal renal 
function.
Besides impaired hepatic or renal function, several 
other factors potentially influence the clearance of 
zidovudine. «An altered pattern of drug metabolism 
has been observed in patients with AIDS compared 
with asymptomatic patients or HIV-negative controls 
[32]. The zidovudine ty2 is increased to approxi­
mately 15 h in neonates, and levels of zidovudine 
and zidovudine glucuronide are nearly equal in neo­
natal plasma [21 22]. However, the glucuronidation 
system rapidly matures and zidovudine pharmaco­
kinetics becomes similar in adults and in infants aged 
about 1 month [33]. Data on zidovudine clearance in 
the elderly are scarce, but type-2 metabolic pro­
cesses, such as glucuronidation, are usually not age- 
dependent [34].
ZDV
ZDV
t
t
AMT
t
ZDV-TP
It
ZDV-DP
ZDV-MP
Cell
J
GZDV
GAMT
▲ Figure 2
Metabolic and elimination pathways of zidovudine 
(ZDV). GZDV: zidovudine glucuronide; AMT: 3'-amino- 
3,-deoxythymidine; GAMT: 3'-amino-3'-deoxythymidine 
glucuronide; MP: monophosphate; DP: diphosphate;
TP: triphosphate
Didanosine
Absorption
The N-glycosidic bond of didanosine is very acid 
labile and in the presence of acid didanosine de­
grades into hypoxanthine and dideoxyribose (Fig. 3). 
The degradation of didanosine in acid (pH 3) is very 
rapid and only 10% of the parent drug remains after
10 min at 37°C [35 36], Therefore, to achieve suffi­
cient bioavailability, didanosine has to be adminis­
tered to fasting patients in combination with antacid. 
The bioavailability of the currently available dida­
nosine formulations Is 40% and 50% for sachets and 
chewable/dispersible tablets, respectively. Despite 
frequent gastrointestinal complaints after ingestion 
of the didanosine tablets, it must be strongly rec­
ommended that didanosine should not be taken 
with food because this reduces the bioavailability of 
didanosine by 50% [37]. In phase-l studies, bioavail­
ability was dose-dependent, suggesting saturation of 
intestinal transport mechanisms or increased degra­
dation in the stomach. In all pharmacokinetic
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Metabolic and elimination pathways of didanosine
(ddl). ddA: 2',3’ -dideoxyadenosine; MP: 
monophosphate; DP: diphosphate; TP: triphosphate
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studies, wide interpatient variability was observed in 
didanosine bioavailability.
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Distribution
Protein binding of didanosine is less than 5%. The 
is about 1.0 l/kg, indicating that it is distributed to 
tissues less than zidovudine, which is possibly due to 
differences in lipid solubility. As is the case with zido­
vudine, knowledge of didanosine distribution into 
specific compartments is relevant, although there are 
fewer data on this topic for didanosine. Pregnancy 
did not appear to influence the Vss of didanosine in 
two HIV-infected women [38]. Didanosine crosses 
the placenta, but placentai/foetai concentrations are 
only 20-50% of maternal concentrations because of 
placental metabolism [38 39]. Studies of the pen­
etration of didanosine into the CSF have been 
hampered by the relatively high detection limits of 
available analytical methods. Experience with CSF 
analyses at our laboratory indicates that didanosine 
levels are 30-50 ng/ml 4 h after a dose of 250 mg. 
CSF concentrations of zidovudine are usually two 
times higher.
Metabolism and excretion
The total body clearance of didanosine is approxi­
mately 1.0 Mr'-kg-1 with 30-50% renal clearance. 
The remaining, non-renal clearance is attributed to 
metabolism and/or biliary excretion. Extensive 
metabolism occurs, via three different metabolic 
pathways, leading to dideoxyadenosine triphos­
phate, the active intracellular form, uric acid and 
purine in the purine metabolic pool, in vitro con­
version to hypoxanthine has been found in erythro­
cytes, indicating that biood samples should be 
centrifuged immediately after collection [40].
As expected, didanosine clearance is reduced in 
patients with renal dysfunction [41]. Haemodialysis 
removes didanosine from plasma, although a 4 h 
dialysis removes only 20% of the didanosine dose. 
Although more data are required, it appears that 
daily administration of 125 mg in tablets is a reason­
able option in patients with end-stage renal failure. 
While the manufacturer recommends that a reduc­
tion in dosage should be considered in patients with 
hepatic dysfunction, there are no data available to 
support this. The pharmacokinetic parameters of 
didanosine appeared to be similar in children and 
adults, with the exception of a lower bioavailability in 
children, although this might be related to inade­
quate antacid doses [42].
Zalcitabine
28
Absorption
Usually, zalcitabine is rapidly and almost completely 
absorbed with a bioavailability of 70-90%. Food 
reduces the rate and extent of absorption.
Distribution
Protein binding of zalcitabine is less than 4%. l/ss is 
about 0.5 l/kg, which is considerably lower than for 
zidovudine or didanosine. Zalcitabine concentrations 
in the CSF are usually below the detection limit of 
high-pressure liquid chromatography methods, but 
using combined chromatographic-mass spectro-
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Figure 4
Metabolic and elimination pathways of zalcitabine 
(ddC). MP: monophosphate; DP: diphosphate; TP,
triphosphate
metric techniques zalcitabine concentrations in the 
CSF of 6-11 ng/ml could be detected 2-3.5 h aftei 
the start of a 1 h infusion.
Metabolism and excretion
So far, no hepatic metabolites of zalcitabine have 
been identified in humans (Fig. 4). A deaminatior 
product, dideoxyuridine, has been found in the 
plasma, urine and CSF of monkeys [43]. Because ol 
the predominant renal elimination pathway of zalci­
tabine, it can be expected that zalcitabine clearance 
depends on creatinine clearance. A population phar­
macokinetic study demonstrated that zalcitabine 
clearance was related to creatinine clearance and to 
body weight [44]. The pharmacokinetics of zalcita­
bine are similar in children and in adults.
Therapeutic drug monitoring of 
antiretroviral agents
For several reasons, the dideoxynucleosides are good 
candidates for therapeutic drug monitoring. First, 
interpatient variability in pharmacokinetic parameters 
is large and this makes the dose a less reliable par­
ameter of drug exposure than the plasma concen­
tration. Furthermore, the toxicity of dideoxynucleo­
side agents is significant and this leads to a narrow 
therapeutic window. However, a therapeutic range 
has not been defined for any of the drugs so far. This 
is mainly due to the difficulty of measuring the phar­
macodynamics of antiretroviral agents. The primary 
endpoint of antiretroviral therapy is a reduction in 
mortality, but the short-term effects are only measur­
able by monitoring surrogate markers, such as CD4 
count, p24-antigenaemia and HIV viraemia. In addi­
tion, the clinical response can also be measured as 
weight gain, decreased energy and reduction of the 
incidence of opportunistic infections, but these are 
rather unspecific endpoints which also depend on, 
for example, chemoprophylaxis. Furthermore, drug- 
related toxicity is common in HlV-infected patients, 
which makes it difficult to attribute a specific toxic 
effect to one drug. It is also known that side-effects
may depend on the stage of disease, as has been 
shown for anaemia induced by zidovudine.
Thus, therapeutic drug monitoring is justified on 
the grounds of the pharmacokinetic properties of the 
antiretroviral agents, but is hindered by unspecific or 
surrogate measurements of antiviral efficacy and 
toxicity. Nevertheless, there are indications that re­
lationships between pharmacokinetic and pharmaco­
dynamic parameters exist Although Balis et al. could 
not demonstrate a relationship between plasma or 
CSF levels of zidovudine and a change in full-scale IQ 
scores in HIV-infected children, a significant relation­
ship between the steady-state concentration of zido­
vudine after continuous infusion and the develop­
ment of neutropenia was observed [45]. Preliminary 
data show that relationships exist between zido­
vudine concentrations and increases in CD4 counts 
[Chiang H et al., unpublished observations] and 
between zidovudine concentrations and anaemia in 
children [46].
For didanosine, these pharmacokinetic-pharmaco­
dynamic relationships have been studied in more 
detail than for zidovudine. These studies have used 
data from several phase-! trials that evaluated a wide 
range of didanosine doses for efficacy and toxicity. 
Drusano et al. demonstrated a significant correlation 
between cumulative didanosine exposure and sup­
pression of circulating p24 antigen [47]. An increase 
in CD4 count was better related to the starting CD4 
count than to the AUC of didanosine. Baltangady et 
al. used the average steady-state plasma concen­
tration (Css), calculated by dividing the average daily 
dose by the apparent oral didanosine clearance and 
related this to the effects of didanosine on CD4 
count, p24 antigenaemia and weight gain in 61 
patients in a 12-week phase-1 trial [48]. Significant 
relationships between didanosine exposure and clini­
cal outcome were observed. Preliminary data also 
suggest that the risk of pancreatitis was related to 
the C5S of didanosine in these phase-l trials [49]. 
Finally, Balis et al. showed that the p24 response and 
a change in full-scale IQ scores were positively re­
lated to the AUC of didanosine in HIV-infected chil­
dren [42].
On the basis of these observations, it appears 
rational to study the concept of therapeutic drug 
monitoring for antiretroviral agents in more detail in 
prospective studies. This should, ultimately, result in 
the definition of a therapeutic range. This concept is 
currently under investigation for 3'-deoxy-3'-fluoro- 
thymidine in a so-called concentration-controlled 
trial [Flexner C, unpublished observations]. Instead of 
escalating doses, patients are monitored for esca­
lating target concentrations. With this approach, a 
therapeutic range might be defined before the drug 
is licensed. For already registered agents, extensive 
post-marketing studies are urgently required to 
obtain more knowledge of pharmacokinetic-phar­
macodynamic relationships.
It could be hypothesized that a relationship 
between the plasma concentration of any antiretro­
viral agent and its antiviral efficacy can never be 
found because it is the intracellular triphosphate 
form that is the active species. For zidovudine, the 
total intracellular concentration of phosphorylated 
zidovudine in a single blood sample was not related 
to the plasma concentration of zidovudine [50].
However, it should be stressed that the triphosphate 
form was not determined separately. In addition, a 
subsequent study from the same investigators 
demonstrated a significant relationship between the 
AUC of intracellular total phosphorylated zidovudine 
and the AUC of zidovudine in plasma [51]. Analytical 
methods for the measurement of intracellular zido­
vudine triphosphate have been developed during the 
last years, but these are extremely labour intensive 
and require large volumes of blood from patients [52 
53]. For these reasons, the measurement of intra­
cellular triphosphates of antiretroviral drugs in 
samples from individual patients is not an acceptable 
option for future large population studies on the 
relationships between pharmacokinetic and pharma­
codynamic parameters. Furthermore, the above­
described results for zidovudine and didanosine 
demonstrate that plasma concentrations are related 
to antiviral efficacy and toxicity, although more 
studies are needed to cast more light on this issue.
Conclusions
The dideoxynucleoside antiretroviral agents have 
some clinical pharmacokinetic properties in common 
(rapid absorption and elimination), but substantial 
differences exist in metabolism, acid lability and 
penetration into the CSF. All agents display wide 
interpatient variability. Knowledge of the pharmaco­
kinetic characteristics is of utmost importance to 
further understand the clinical effects of this class of 
agents. Concentration-controlled clinical trials should 
be included in the drug development process of all 
new agents. Prospective, post-marketing studies with 
approved drugs are needed to determine a possible 
therapeutic range.
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